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Abstract
Background According to surveys, many patients with advanced
cancer wish to receive survival information.
Objective This study investigated information preferences by oﬀer-
ing patients a decision aid (DA) with information on expected sur-
vival for two treatment options: supportive care with or without
second-line palliative chemotherapy. Predictors of accepting sur-
vival information were explored.
Design Eligible patients in this multicentre prospective study were
oﬀered second-line chemotherapy for advanced breast or colorectal
cancer. A nurse presented a DA on second-line treatment and
asked patients whether they desired information on (i) adverse
events, (ii) tumour response and (iii) survival. Data on 50 clinical
and psychosocial patient characteristics were collected from inclu-
sion forms and patient questionnaires.
Results Seventy-seven patients received a DA; median age
62 years (range 32–80), 61% female, 77% colorectal cancer. Fifty-
seven patients (74%; 95% CI 64–84) desired survival information.
Four psychosocial characteristics (e.g. deliberative decision style)
independently predicted information desire. However, the use of
these characteristics to predict information desire hardly outper-
formed a simple prediction rule.
Conclusions Many patients desired information on expected sur-
vival when deciding about second-line treatment. However, our
exploratory analysis indicated that patients desiring this informa-
tion could not be identiﬁed based on their clinical or psychosocial
characteristics. These ﬁndings can help encourage candid discus-
sions about expected survival. Health professionals should be care-
ful not to make implicit assumptions of information desire based
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on patient characteristics, but to explicitly ask patients if survival
information is desired, and act accordingly.
Introduction
A central component of the communication
with patients with advanced cancer is the dis-
cussion of prognosis, including expected sur-
vival. Health professionals may be concerned
that providing survival information could be
contrary to patients’ wishes or best interests.1
While patients with advanced cancer indeed
fear bad news, many wish to receive survival
information to make treatment decisions and
plan the future.2 Candid conversations about
prognosis can establish an open atmosphere,
improve patients’ sense of control and facilitate
more realistic expectations.3 Surveys found that
many patients with advanced cancer (44, 59, 80
and 88%, respectively) stated a desire for
survival information.4–7 It remains unclear,
however, how many patients will accept
survival information when it is actually oﬀered
by a health professional.8
Previous studies have tried to characterize
patients desiring survival information. In these
studies, patients were asked whether they
desired to discuss expected survival6,7,9 or
whether they desired these discussions had taken
place.4,10 Among patients with advanced cancer,
a higher information desire was observed for
men4,10 and for patients with higher education,7
more pain,7 or more symptoms of depression.6
In addition, among patients with cancer across
all disease stages, stating a desire for survival
information was associated with lower age,
lower death avoidance and worse prognosis.9
This study will assess preferences of patients
with advanced breast or colorectal cancer for
receiving survival information when deciding
whether or not to start second-line palliative
chemotherapy. Patients’ information desire will
be assessed by actually oﬀering information on
the expected beneﬁts and risks of chemotherapy,
using a decision aid (DA). Clinical and psycho-
social patient characteristics associated with
desiring survival information will be explored.
Methods
Design
This study was part of a randomized trial
(Netherlands Trial Register; NTR1113) con-
ducted in 17 hospitals in the Netherlands which
was described in detail elsewhere.11 In short,
the target population consisted of patients with
advanced breast or colorectal cancer facing the
decision whether or not to start second-line
palliative chemotherapy. To identify these
patients, patients who were in remission after
ﬁrst-line chemotherapy or were receiving ﬁrst-
line chemotherapy were preselected. Exclusion
criteria were labile personality structure (as
assessed by the physician), a Karnofsky perfor-
mance score lower than 60, and insuﬃcient
Dutch language proﬁciency. The study was
approved by the regional ethics review commit-
tee and the research ethics committees of all
participating centres.
Procedure
The medical oncologist or nurse assessed the
potential eligibility of consecutive patients. Pro-
fessionals were instructed not to mention that
explicit survival information could be provided,
to avoid losing patients not desiring such infor-
mation. Professionals asked patients for per-
mission to be approached by the researcher,
who obtained written informed consent.
At inclusion, patients were sent a baseline
questionnaire with sociodemographic and psy-
chosocial variables hypothesized to be associ-
ated with information desire. These patients
were monitored for disease progression and the
ensuing treatment decision whether or not to
start second-line palliative chemotherapy.
Patients who were oﬀered second-line treat-
ment were randomly assigned to receive (i) the
usual treatment-related information from the
oncologist (control group) or (ii) the usual
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treatment-related information from the oncolo-
gist followed by a DA from a nurse (interven-
tion group) (1 : 2 ratio).
This study focused on the patients in the
intervention group, who received the DA in a
subsequent consultation with a nurse, typically
within a week after the consultation with the
oncologist who mentioned disease progression
and treatment options. DAs were developed
for 11 chemotherapeutic regimens commonly
used as second-line treatment for advanced
breast or colorectal cancer, based on systematic
reviews of the literature for the two tumour
types.12,13 In the systematic review on beneﬁts
and risks of second-line irinotecan for
advanced colorectal cancer, 25 phase II and 5
phase III studies were identiﬁed. Median sur-
vival was established using the single direct
randomized comparison between patients
receiving BSC plus second-line irinotecan and
patients receiving BSC alone.12 In the vast
body of literature on second-line chemotherapy
for breast cancer, no randomized studies com-
paring any of the second-line chemotherapeutic
regimens to BSC alone were found. A meta-
analysis was performed to establish the median
survival for each of the selected chemothera-
peutic regimens; no diﬀerences in eﬀectiveness
were found between the regimens.13 In the
DAs, the median expected survival of
12 months with chemotherapy was presented
together with a question mark for expected
survival without chemotherapy, and an expla-
nation that it is not known whether, or in what
way, the survival of patients with advanced
breast cancer is inﬂuenced by second-line
chemotherapy.
Figure 1 shows a summary of the informa-
tion provided in a DA for colorectal cancer,
and a full DA is available in the online
supplement.
The consultation started with an introduc-
tion in which the DA, the two treatment
options (supportive care with or without sec-
ond-line palliative chemotherapy), and an
example of risk information were presented.
Then, the nurse proceeded to oﬀer information
on risks and beneﬁts in three separate items: (i)
adverse events; (ii) tumour response; and (iii)
survival. For each item, the nurse ﬁrst elabo-
rated on the type of information that could be
expected (e.g. implications of a serious adverse
event, the temporary nature of tumour
response, the concept of median survival) and
then asked the patient whether the information
was desired or not. If desired, the nurse pro-
vided the information. The instructions for the
nurse, including the explanation of the concept
of median survival, are included in the online
supplement.
Measures
Table 1 gives an overview of the measurements
of information desire and potential predictors.
Information desire
During the interview with the DA, the nurse
registered the main outcome measure: whether
or not the patient wanted to see the informa-
tion on survival (see above in ‘Procedure’).
Potential predictors of information desire
Sociodemographic variables were collected
through the baseline questionnaire and the
inclusion form (Table 1). Oncologists were
instructed to record tumour and treatment
characteristics on the inclusion form and to
estimate patient survival on the progression
form. At the start of the interview, the nurse
asked for the patient’s treatment preference and
if applicable, the strength of this preference.
Measures on well-being included general health,
anxiety and depression,14 cancer worries15 and
health-related quality of life.16 Questions on
coping included coping with cancer,17 decision
style,18 participation preference19 and death
avoidance.9,20 Information-related measures
included the amount of information preferred,21
the amount of information received and numer-
acy22,23 (i.e. the ability to handle basic probabil-
ity concepts). Patients rated their own baseline
knowledge (subjective knowledge) on cancer
and on beneﬁts and risks of treatment options.
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Patients’ attitudes were measured with ques-
tions on striving for length (quantity) and qual-
ity of life,24 questions on the patients’ perceived
amount of beneﬁts and risks experienced during
ﬁrst-line chemotherapy and a question on the
time since last chemotherapeutic treatment.
Statistical analysis
To examine selective attrition, the characteris-
tics of patients receiving the DA were com-
pared with patients experiencing progressive
disease who were not randomized, using an
independent-samples t-test or chi-square test.
As the main outcome of this study, we calcu-
lated the percentage of patients, including the
95% conﬁdence interval of that percentage,
who accepted the survival information. Next,
an extensive exploratory analysis of potential
predictors of accepting survival information
was performed. Patients desiring survival infor-
mation were compared with patients not desir-
ing that information, using chi-square tests. In
case of missing data, scale values were calcu-
lated only if at least half of the items were
available, by imputing the mean of the
available items. Data were dichotomized by a
median split, except for HADS anxiety and
depression scales which were dichotomized
using a clinical cut-oﬀ point of 8.25 Patient
characteristics associated with desiring survival
information at a level of P < 0.2 in a bivariate
analysis were entered stepwise in a multivari-
able logistic regression model, adding addi-
tional variables with a P value of <0.05. The
use of a higher value of P for the selection of
Figure 1 Example of the summary page
of a decision aid for colorectal cancer.
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Table 1 Overview of measurements of information desire and predictors
Variable Operationalization
Timing of measurements
Inclusion
Interview
with DA
Information desire P
Predictors of information desire
Sociodemographics (n = 8)
Age P
Living situation P
Working status P
Having children P
Having grandchildren P
Education P
Religion P
Gender O
Tumour and treatment
characteristics (n = 7)
Date of initial diagnosis of disease O
Date of diagnosis metastatic disease O
Tumour location O
Tumour status O
Previous palliative chemotherapy O
First-line chemotherapy in study
setting
O
Estimate of patient survival 3–6, 6–9, 9–12, >12 months O1
Decision-related measures (n = 2)
Treatment preference Chemotherapy+BSC/BSC alone/do
not know
P
Strength of treatment preference 1–4 (not strong–very strong)2 P
Well-being (n = 13)
General health 0–10 (worst-best imaginable) P
Anxiety and depression HADS Anxiety and Depression Scale P
Cancer Worries Adapted Lerman’s Cancer Worry Scale P
Health-related quality of
life (n = 9)3
EORTC QLQ-C15-PAL P
Coping (n = 9)
Coping with cancer (n = 3)4 Mental Adjustment to Cancer Scale P
Decision style (n = 4)5 Michigan Assessment of Decision Style P
Participation preference Problem-Solving Decision-Making Scale P
Death avoidance Death Avoidance Scale P
Information-related measures (n = 5)
Information preference 0–10 (I want to know nothing-everything
there is to know)
P
Amount of information received 1–7 (way too little–way too much) P
Subjective numeracy (n = 3)6 Subjective Numeracy Scale P
Knowledge-related measures (n = 1)
Subjective knowledge 1–10 (very bad–excellent) P
Treatment attitudes (n = 5)
Striving for length or quality
of life (n = 2)7
QQ-Questionnaire P
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variables in the bivariate analysis is generally
recommended because the use of the traditional
value of P < 0.05 can result in missing impor-
tant predictors, concealed by confounding.
Results
Participants
Of 441 patients assessed for potential eligibil-
ity, 86 (20%) did not meet the inclusion crite-
ria, and 34 patients (8%) were not approached
by the oncologist and therefore the inclusion
criteria could not be veriﬁed (see Fig. 2). Of
the 321 patients asked for the study, 263 (82%)
gave informed consent. Of them, 92 patients
(35%) were not faced with the decision on sec-
ond-line palliative chemotherapy and therefore
did not belong to the target population of this
study. Another 43 patients (16%) faced the
treatment decision but were not randomized
and dropped out of the study. Of the 128
patients who experienced disease progression
and were randomized, 83 were assigned to the
intervention group, of which 77 (93%) received
the DA.
No signiﬁcant diﬀerences were found
between the 43 patients with progressive dis-
ease who were not randomized and the 77
patients who received the DA on the variables
of gender (60 vs. 61% female; P = 0.872), age
(mean 59.6 vs. 61.0; P = 0.470), education (col-
lege education 25 vs. 30%; P = 0.592), employ-
ment (45 vs. 41%; P = 0.751), information
preference at baseline (mean scores 8.3 vs. 8.5;
P = 0.458) and general health (mean scores 6.7
vs. 6.4; P = 0.422). However, non-randomized
patients more often had a tumour of the breast
(vs. colon or rectum) than patients receiving
the DA (43 vs. 23%; P = 0.027).
Information desire
Of 77 patients receiving the DA, 74 (96%)
desired the information on adverse events, 70
(91%) desired the information on tumour
response, and 57 (74; 95% CI 64–84) desired
the information on survival.
Potential predictors of information desire
Of 50 patient characteristics considered, 15
(30%) were associated with information desire
at the level P < 0.2 (see Table 2). Patients who
desired survival information were more likely
to be unemployed or male, more recently
received the initial diagnosis of disease, and
more often had a tumour of the colon or rec-
tum (vs. breast). In addition, desiring survival
information was associated with more symp-
toms of nausea and vomiting, pain and dysp-
noea. Patients desiring survival information
Table 1 Continued
Variable Operationalization
Timing of measurements
Inclusion
Interview
with DA
Perceived benefits and harms of
first-line chemotherapy (n = 2)8
1–4 (much–none) P
Time since last chemotherapy 1–5 (currently under treatment–more
than a year ago)
P
P, patient-reported; O, oncologist-reported; BSC, best supportive care; DA, decision aid.
1Reported on the progression form when disease progression occurred.
2For patients who were undecided, strength of the treatment preference was scored as ‘0’.
3Including physical and emotional functioning, fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation.
4Including helplessness/hopelessness, cognitive avoidance, fighting spirit.
5Including decision avoidance, deferring responsibility, information seeking, deliberation.
6Including the total scale and the ability and preference subscales.
7Including striving for length of life and striving for quality of life.
8Including benefits and harms of first-line palliative chemotherapy.
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employed less cognitive avoidant and ﬁghting
spirit cancer coping styles, deferred less respon-
sibility and deliberated more regarding decision
making. Desire for survival information was
higher in patients with a lower perceived
numerical ability, lower subjective knowledge
and perception of greater beneﬁt and lesser
harm from ﬁrst-line chemotherapy. The multi-
variable model was ﬁtted twice; once with all
15 predictors and once with 14 predictors, as
the variable ‘employment status’ was only
available for a subgroup of patients under age
65 (retirement age in the Netherlands at the
time of the study) (n = 53). Both models
showed that greater perceived beneﬁt of ﬁrst-
line chemotherapy (OR 7.4; 95% CI 1.8–30.8),
lower cognitive avoidance (OR 0.1; 95% CI
0.0–0.7), lower ﬁghting spirit (OR 0.2; 95% CI
0.0–0.8) and higher deliberation decision style
(OR 4.9; 95% CI 1.1–21.1) were four indepen-
dent predictors of desiring survival informa-
tion. The odds ratios presented are derived
from the model ﬁtted with 14 predictors.
Applying these four characteristics, desiring
survival information was correctly predicted in
60 of 72 patients with complete data (83%
correct). Incorrect predictions included overes-
timations for eight patient (11%) and underes-
timations for four patients (6%). By way of
comparison, simply assuming that all 72
Figure 2 Patient flow chart.
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Table 2 Patient characteristics associated with information desire at P < 0.2.
Acceptance of survival information Bivariate analysis
Yes
n = 57 (74%)
No
n = 20 (26%)
v2 OR (95% CI) P
Sociodemographics
Working status1
Unemployed 24 (80%) 6 (20%) 4.4 0.3 (0.1–0.9) 0.037
Employed 11 (52%) 10 (48%)
Gender
Male 26 (87%) 4 (13%) 4.4 0.3 (0.1–1.0) 0.037
Female 31 (66%) 16 (34%)
Tumour and treatment characteristics
Time since initial diagnosis of disease
Short (<35 months) 33 (87%) 5 (13%) 5.9 0.3 (0.1–0.8) 0.015
Long (≥35 months) 24 (63%) 14 (37%)
Tumour location
Breast 11 (61%) 7 (39%) 1.9 2.3 (0.7–7.0) 0.165
Colon or rectum 46 (78%) 13 (22%)
Well-being: HRQoL
HRQoL: nausea and vomiting
Low (0) 32 (68%) 15 (32%) 3.3 2.9 (0.9–9.9) 0.068
High (>0) 25 (86%) 4 (14%)
HRQoL: pain
Low (<16.7) 32 (70%) 14 (30%) 1.9 2.2 (0.7–6.9) 0.167
High (≥16.7) 25 (83%) 5 (17%)
HRQoL: dyspnoea
Low (0) 34 (69%) 15 (31%) 2.5 2.5 (0.7–8.6) 0.117
High (>0) 23 (85%) 4 (15%)
Coping
Coping with cancer: cognitive avoidance
Low (<2.5) 30 (88%) 4 (12%) 6.1 0.2 (0.1–0.8) 0.014
High (≥2.5) 27 (64%) 15 (36%)
Coping with cancer: fighting spirit
Low (<3) 31 (86%) 5 (14%) 4.7 0.3 (0.1–0.9) 0.031
High (≥3) 26 (65%) 14 (35%)
Decision style: deferring responsibility
Low (<4.7) 40 (80%) 10 (20%) 1.9 0.5 (0.2–1.4) 0.169
High (≥4.7) 17 (65%) 9 (35%)
Decision style: deliberation
Low (<4.4) 23 (62%) 14 (38%) 6.5 4.1 (1.3–13.1) 0.011
High (≥4.4) 34 (87%) 5 (13%)
Information-related measures
Subjective Numeracy: ability subscale
Low (<5) 30 (83%) 6 (17%) 2.6 0.4 (0.1–1.2) 0.108
High (≥5) 27 (68%) 13 (33%)
Knowledge-related measures
Subjective knowledge
Low (<6.3) 31 (86%) 5 (14%) 4.0 0.3 (0.1–1.0) 0.045
High (≥6.3) 26 (67%) 13 (33%)
Treatment attitudes
Perceived benefits first-line chemotherapy
Low (<2) 13 (54%) 11 (46%) 8.3 5.1 (1.6–15.8) 0.004
High (≥2) 42 (86%) 7 (14%)
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patients would accept survival information
already correctly identiﬁed 55 patients desiring
information (76%).
Discussion
This study showed that the large majority of
patients with advanced breast or colorectal
cancer (74%) desired to be informed about sur-
vival when facing a decision on second-line pal-
liative treatment. An extensive exploration of
patient characteristics associated with actual
acceptance of survival information yielded four
characteristics, related to past experience and
coping with cancer and decision-making styles,
associated with desiring survival information.
However, these characteristics were not very
helpful in correctly identifying patients desiring
survival information. Simply assuming that all
patients desire survival information would
already identify most of these patients
correctly.
Previous studies reported that a large pro-
portion of patients with advanced cancer (44,
59, 80 and 88%, respectively) stated a desire
for survival information.4–7 In the present
study, we went a step further by oﬀering treat-
ment-related information to patients who faced
a palliative treatment decision. This informa-
tion was oﬀered by a nurse using a DA. We
found that a high percentage of patients (74%)
wished to receive the information when it was
actually oﬀered to them.
Some of the patient characteristics associated
with acceptance of survival information have
previously been reported to be associated with
a stated desire for survival information. This
includes the ﬁnding that men4,10 and patients
with more pain7 were more likely to desire sur-
vival information. Likewise, our data mildly
suggested that patients experiencing more nau-
sea, vomiting and dyspnoea desired more infor-
mation. We will not elaborate on these ﬁndings
because of the limited practical value for pre-
dicting information desire. Reported predictors
of preferences for survival information not
conﬁrmed in this study include higher educa-
tion,7,9 higher depression scores6 and lower
death avoidance.9 Furthermore, the previously
reported relation between higher desire for sur-
vival information and worse patient-reported
prognosis9 was not conﬁrmed when oncolo-
gists’ estimate of survival was used. Age was
not found to be related to desiring survival
information; previous studies showed mixed
results for age.7,9 Hypothesized predictors of
desiring survival information that were not
conﬁrmed in this study included (strength of)
patients’ treatment preference, cancer worries,
information and participation preferences, and
striving for length vs. quality of life.
Despite extensive modelling, patients desiring
survival information could not be identiﬁed
using psychosocial and clinical characteristics.
We do not recommend that any of the charac-
teristics are used to decide whether or not to
oﬀer survival information to a patient. Apart
from the fact that the identiﬁed characteristics
are not easily assessable, (at least) 11% of
patients would receive undesired survival infor-
mation, while another 6% would be denied
desired information.
The main strength of this study is that
patients’ desire for survival information was
investigated by oﬀering information to patients
who actually faced a treatment decision. To
Table 2 Continued
Acceptance of survival information Bivariate analysis
Yes
n = 57 (74%)
No
n = 20 (26%)
v2 OR (95% CI) P
Perceived harms first-line chemotherapy
Low (<2) 10 (91%) 1 (9%) 1.9 0.3 (0.0–2.3) 0.172
High (≥2) 47 (73%) 17 (27%)
1Selection of 51 patients below the age of 65 (retirement age in the Netherlands at the time of the study).
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minimize selection bias, we preselected patients
who would potentially face the treatment deci-
sion, applying few exclusion criteria, and
instructed professionals not to tell patients
beforehand that detailed survival information
would be oﬀered in the DA. A satisfactory
informed consent rate of 82% was achieved.
A limitation to the generalizability of the
results is that we selected only patients with
advanced breast or colorectal cancer, deciding
about second-line palliative chemotherapy. For
both tumour types, a substantial majority of
patients (78% of colorectal and 61% of
patients with breast cancer, respectively)
desired survival information. The generalizabil-
ity of our ﬁndings to patients with other
tumour types or patients facing other palliative
treatment decisions needs further study.
The exploration of predictors of accepting
survival information was extensive, but has
several limitations. Patients ﬁlled out the base-
line questionnaire several months (median 3;
IQR 0–9) before the survival information was
oﬀered. It is possible that certain patient char-
acteristics (e.g. well-being) changed over these
months. Thus, the predictive performance of
the model might have been better had more
recent patient data been used. However, a
lengthy questionnaire at the time of disease
progression was judged to be infeasible. The
generalizability of the identiﬁed patient charac-
teristics to other populations is questionable.
First, there is the issue of multiple testing. In
the bivariate analysis, 15 of 50 patient charac-
teristics (30%) were found to be associated
with information desire, while 10 characteristics
(20%; P < 0.2) were expected to be found due
to chance alone. Second, the multivariable
regression model is likely overﬁtted, for
instance due to the high number of patient
characteristics in relation to the number of
patients.26 Larger studies are needed to conﬁrm
the ﬁndings on patients’ information desire and
potential predictors.
The ﬁnding that many patients wanted to
receive information on expected survival
regarding second-line chemotherapy can help
encourage candid discussions between health
professionals and patients. Our recommenda-
tion to health professionals is not to make
implicit assumptions of information desire
based on patient characteristics, but to explic-
itly ask patients if survival information is
desired, and then act accordingly. The use of
open-ended questions can help to elicit a
patient’s most important questions and con-
cerns as well as the preferred level of candid-
ness, to guide the provision of information by
the clinician.27 For example, a physician might
ask ‘How much would you like to know?’ or
more speciﬁcally ‘Do you want me to tell you
how long patients can live with this kind of
cancer with or without chemotherapy? What
kind of information do you want me to
cover?’.3,28
DAs can support professionals and patients
in conversations about treatment options by
providing numerical estimates of expected sur-
vival, including visual aids, for each treatment
option. DAs are proven to be eﬀective at
improving knowledge and realistic perceptions
of outcomes and increasing patients’ involve-
ment.29 In the current study, DAs were oﬀered
to patients by nurses, because nurses usually
spend more time with patients than physicians,
and some nurses are already highly involved in
supporting treatment decisions.30,31 A possible
amendment to the DAs used in this study, as
recommended in a recent study exploring pref-
erences of people with a cancer experience, is
the presentation of three survival scenarios
(best case, worst case and typical survival)
instead of median survival.32 These scenarios
would better convey the variation in survival
duration and help patients to hope for the best
while planning for the worst.
Conclusion
Our ﬁndings indicate that many patients with
advanced breast or colorectal cancer want to
receive survival information when deciding
about second-line palliative chemotherapy. It
is, however, diﬃcult to identify those patients
who desire the information. Candid conversa-
tions about expected survival are particularly
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relevant in the context of treatment decisions,
when the potential beneﬁts of treatment have
to be weighed up against the risks. Decision
aids can be valuable tools to support profes-
sionals and patients in these conversations.
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